Xtant Medical Stock Forum

$Xtant Medical (XTNT.US)$
In today's earnings report, Xtant Medical Holdings (XTNT) announced record-breaking third-quarter revenue of $25 million, representing a year-over-year growth of over 30%. This impressive growth was driven by increased demand across its portfolio of regenerative medicine and surgical solutions. The company also reported a strong improvement in gross margins, highlighting a successful reduction in costs and operational efficiencies. However, despite revenue gains, XTNT no...

$Xtant Medical (XTNT.US)$ Xtant Medical Expands Product Portfolio With Launch of Its Own Viable Bone Matrix, OsteoVive(R) Plus
Accesswire· 10 mins ago
New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics

$Xtant Medical (XTNT.US)$ Revenue of $27.9 million, up 55%, compared to the prior year quarter
Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter
Net loss of $4.4 million compared to $2.1 million in the year ago quarter
Positive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of $0.3 million in the prior year quarter

$Xtant Medical (XTNT.US)$ Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds 25 minutes ago, 5:00 AM EDT Via GlobeNewswire

$Xtant Medical (XTNT.US)$ Fourth quarter 2023 revenue grew 84.1% to $28.1 million, compared to $15.3 million for the same quarter in 2022. Full year 2023 revenue grew 58% to $91.3 million, compared to $58.0 million for 2022. These revenue increases are attributed primarily to greater independent agent and private label sales, sales from the acquired Coflex and CoFix product lines, and sales from the acquisition of Surgalign.
Gross margin for the fourth quarter of 2023 was 61.0%, co...

$Xtant Medical (XTNT.US)$ Xtant Medical Announces Record Third Quarter Revenue of $25 Million
Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million